Global capabilities
Delivering value beyond the test result
At Mayo Clinic Laboratories, laboratory medicine is about more than a test result — it’s about everything that contributes to providing answers for your patients. We develop individualized support solutions for each client that extend through all aspects of the relationship to ensure the delivery of answers, not just results.
Specialized testing areas include:
Global logistics and shipping
We develop unique relationships with each client to individualize logistics support, which is coordinated by a local team who ensures a seamless process before the first patient specimen is sent. Our specialists collaborate with packaging suppliers to create unique solutions that extend the stability of specimens traveling around the world.
These experts ensure specimens are handled carefully and efficiently through close connections to shipping carriers. The air carriers we work with are experienced with processing clinical specimens.
Optimized, expeditious processing
We recognize many medical conditions have a window of opportunity for the best possible outcomes. Our tests and processes are optimized to better serve patients and deliver results with outcomes in mind. We do not triage specimens across a network of labs or use a batch-testing business model. Result turnaround times are expedited by:
- Running tests continuously – your samples are processed alongside those from Mayo Clinic.
- A testing approach that incorporates comprehensive panels and algorithms when appropriate.
- Utilization of Lean and Six Sigma processes.
Reliable connectivity
We offer technology solutions to help our clients connect to us, including a secure online portal with interfacing capabilities that allows you to easily order tests and receive results. Our solutions include:
- Client-friendly test ordering through MayoLINK, which is available in eight languages.
- Expansive website with links to our open- access test catalog, which is updated daily and features comprehensive clinical information, including specimen requirements; clinical and interpretative information; performance; sample test reports; setup files; and pricing.
- 30 country-specific toll-free numbers.
News and updates
The latest
Dr. Bill Morice shares how clinical diagnostics are expanding to guide treatment and enable clinicians to target therapies more precisely.
In February 2021, Mayo Clinic Laboratories announced three new tests along with numerous reference value changes, obsolete tests, and algorithm changes.
In this month’s “Hot Topic,” Julia Lehman, M.D., discusses serologic testing for Celiac Disease in patients with IgA deficiency.
Controlled substance testing options vary in the details they provide about patient drug use, painting an incomplete picture of usage patterns that can hinder accurate prescription monitoring and treatment outcomes. However, a new comprehensive Controlled Substance Monitoring Panel, developed by the Clinical and Forensic Toxicology Laboratory at Mayo Clinic Laboratories, offers in-depth analysis on more than 70 different prescription medications and illicit substances to provide clinicians with details and interpretations on patients’ controlled substance use lacking in other laboratory assays.
A study involving Mayo Clinic investigators that examined new approaches to the diagnosis of heparin-induced thrombocytopenia has been met with enthusiasm in the scientific community.
This week’s research roundup features a study on the management of patients with giant cell myocarditis.
Top highlights include: The impact COVID-19 has had on women, SARS-CoV-2 mutations explained, and expert answers about the new COVID-19 vaccine.
In this episode, Dr. Allan Klompas, assistant professor of anesthesiology and physician in the Department of Anesthesiology at Mayo Clinic, discusses transfusion support of extracorporeal membrane oxygenation (ECMO) patients.
William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and president of Mayo Clinic Laboratories, joins the "Answers From the Lab" podcast for his weekly leadership update. March is Women's History Month, and in this episode, Dr. Morice and Bobbi Pritt, M.D., mark the occasion by discussing the legacy of female leaders at Mayo Clinic.
As she heads toward retirement at the end of March, Rita Baird looks back on her career at Mayo Clinic Laboratories and discusses her role working with MCL clients as a regional service representative.
This week’s research roundup features a phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients With ABC-type diffuse large b-cell lymphoma.
In an article in The Globe and Mail, Matthew Binnicker, Ph.D., discussed factors that could be contributing to the recent drop in case counts.
The following list includes updates posted to mayocliniclabs.com during the month of February.